## KVUE: Kenvue Inc. - XLP: Consumer Defensive

### Executive Summary

VALUE thesis: PEG 0.88 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($16.54)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Orion Porfolio Solutions LLC Purchases 66,112 Shares of Kenvue Inc. $KVUE**
- Source: MarketBeat | 20251216T113625 | Neutral | Relevance: 100%
- Orion Portfolio Solutions LLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 30.4%, purchasing an additional 66,112 shares to now hold 283,590 shares valued at $5.94 million. The article also notes significant insider buying from Director Jeffrey C. Smith and highlights analyst ratings, with the stock currently holding an average "Hold" rating and a consensus target price of $20.23. Kenvue offers a quarterly dividend with a yield of approximately 4.8%, but faces a high payout ratio of 110.67%.

**2. Insider Buying: Kenvue (NYSE:KVUE) Director Buys 3,200,000 Shares of Stock**
- Source: MarketBeat | 20251215T223210 | Neutral | Relevance: 100%
- Kenvue (NYSE:KVUE) Director Jeffrey Smith purchased 3,200,000 shares of the company's stock for $55.58 million on December 12th, increasing his stake by 13.27% to a total of 27,307,632 shares. This significant insider buying comes as Kenvue experiences a falling stock price and faces analyst downgrades, despite beating recent EPS estimates. The company's high dividend payout ratio of 110.67% raises concerns about dividend sustainability.

**3. Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)**
- Source: ts2.tech | 20251215T133223 | Neutral | Relevance: 100%
- Kenvue Inc. (NYSE: KVUE) stock is currently trading around $17.3, below the implied value of the Kimberly-Clark acquisition offer of approximately $18.59, reflecting market concerns about the deal's timeline, risks, and ongoing Tylenol litigation. Key factors influencing the stock include the S-4 filing progress, shareholder sentiment, and legal developments, particularly the Texas Attorney General's lawsuit against Johnson & Johnson and Kenvue. Despite the acquisition context, Kenvue's recent operational performance shows a decline in net sales and organic sales, with reaffirmed FY2025 modest outlook.

**4. Troy Asset Management Ltd Lowers Position in Kenvue Inc. $KVUE**
- Source: MarketBeat | 20251215T125236 | Neutral | Relevance: 100%
- Troy Asset Management Ltd has reduced its stake in Kenvue Inc. (NYSE:KVUE) by 7.7%, selling 75,037 shares and now owning 902,075 shares valued at $18.88 million. Despite this, institutional ownership remains high at 97.64%, with a "Hold" consensus rating and a $20.23 average target price from analysts. Kenvue exceeded quarterly EPS estimates with $0.28, but revenue saw a 3.5% year-over-year decline.

**5. Insider Buying: Kenvue (NYSE:KVUE) Director Acquires 3,177,694 Shares of Stock**
- Source: MarketBeat | 20251215T224410 | Neutral | Relevance: 100%
- Kenvue (NYSE:KVUE) Director Jeffrey Smith recently acquired 3,177,694 shares of the company's stock for over $55 million, increasing his direct stake to 24,107,632 shares. Kenvue's dividend yield is 4.8%, but its payout ratio of 110.67% raises sustainability concerns. The company reported $0.28 EPS for the last quarter and provides FY2025 EPS guidance of $1.00-$1.05, while analysts hold a consensus "Hold" rating with a $20.23 price target.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (+0.0%)
- Blackrock Inc.: 7.6% (-1.9%)
- Price (T.Rowe) Assoc: 6.0% (-31.5%)
- State Street Corpora: 6.0% (-0.2%)
- FMR, LLC: 4.7% (-9.3%)

### Key Risks

1. Long-term trend broken: trading 14.6% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +3.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.88 indicates undervaluation relative to growth. Forward P/E 15.6x stretched relative to 7% growth. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $33.1B |
| Beta | 0.56 |
| 52W Range | $14.02 - $25.17 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.88 |
| Forward P/E | 15.6 |
| Current P/E | 16.7 |
| YoY Growth | 7.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.8% to 3.9% (+3.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.1pp (needs >4.0% for momentum thesis). MRS_5 at 2.0% confirms short-term momentum alignment. Below SMA200 (0.85x), long-term trend not supportive. RSI neutral at 60. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.91% (CS: 66) | Neutral |
| RSI_14 | 59.8 | Neutral |
| MACD Histogram | 0.00 | Bearish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.064x | Above |
| vs SMA200 | 0.854x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $17.30
- **Stop Loss:** $16.54 (4.4% risk)
- **Target:** $18.82 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1421
- **Position Value:** $24,583.30
- **Portfolio %:** 24.58%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-05 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.26 | $0.28 | +5.7% |
| 2025Q2 | $0.28 | $0.29 | +2.2% |
| 2025Q1 | $0.23 | $0.24 | +5.4% |
| 2024Q4 | $0.26 | $0.26 | +1.5% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*